PE20130815A1 - Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos - Google Patents

Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos

Info

Publication number
PE20130815A1
PE20130815A1 PE2013000114A PE2013000114A PE20130815A1 PE 20130815 A1 PE20130815 A1 PE 20130815A1 PE 2013000114 A PE2013000114 A PE 2013000114A PE 2013000114 A PE2013000114 A PE 2013000114A PE 20130815 A1 PE20130815 A1 PE 20130815A1
Authority
PE
Peru
Prior art keywords
metabolic disorders
composition
methods
pharmaceutical combination
treat diabetes
Prior art date
Application number
PE2013000114A
Other languages
English (en)
Spanish (es)
Inventor
Oleg Iliich Epshtein
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130815(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru
Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of PE20130815A1 publication Critical patent/PE20130815A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2013000114A 2010-07-21 2011-07-15 Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos PE20130815A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010130348/15A RU2531048C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127051/15A RU2509572C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами

Publications (1)

Publication Number Publication Date
PE20130815A1 true PE20130815A1 (es) 2013-07-18

Family

ID=44899155

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000114A PE20130815A1 (es) 2010-07-21 2011-07-15 Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos

Country Status (30)

Country Link
US (1) US8617555B2 (enExample)
EP (2) EP2595658A2 (enExample)
JP (2) JP2013533268A (enExample)
KR (2) KR20130103486A (enExample)
CN (1) CN103118707A (enExample)
AR (1) AR082312A1 (enExample)
AU (1) AU2011281240B2 (enExample)
BR (1) BR112013001299A2 (enExample)
CA (1) CA2805961A1 (enExample)
CL (1) CL2013000200A1 (enExample)
CZ (1) CZ2013124A3 (enExample)
DE (1) DE112011102396T5 (enExample)
DK (1) DK201370089A (enExample)
EA (1) EA029847B1 (enExample)
EE (1) EE05761B1 (enExample)
ES (1) ES2445846R1 (enExample)
FI (1) FI20135152L (enExample)
FR (1) FR2962913A1 (enExample)
GB (2) GB2496799B (enExample)
IT (1) ITTO20110627A1 (enExample)
LT (1) LT5980B (enExample)
MX (1) MX2013000804A (enExample)
MY (1) MY160979A (enExample)
NO (1) NO20130265A1 (enExample)
NZ (1) NZ606964A (enExample)
PE (1) PE20130815A1 (enExample)
PH (1) PH12013500140A1 (enExample)
SE (1) SE1350212A1 (enExample)
SG (1) SG187578A1 (enExample)
WO (1) WO2012010966A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
CA2654408C (en) * 2006-06-06 2018-05-08 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
CZ2013105A3 (cs) * 2010-07-15 2013-05-22 Iliich Epshtein@Oleg Zpusob zvýsení úcinku aktivované potencované formy protilátky
EP2593474A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
DE112011102349T5 (de) 2010-07-15 2013-04-18 Oleg Iliich Epshtein Pharmazeutische Zusammensetzung und Behandlungsverfahren
AU2011281247B2 (en) 2010-07-21 2015-07-30 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
WO2012010970A2 (en) 2010-07-21 2012-01-26 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
BR112013001296A2 (pt) * 2010-07-21 2017-12-19 Lliich Epshtein Oleg composições farmacêuticas e respectivo uso e métodos de tratamento de vertigem de diferentes origens, cinetose e distonia vascular vegetativa
CN103154030A (zh) * 2010-08-06 2013-06-12 奥列格·伊里奇·爱泼斯坦 复合药物组合物以及对传染性疾病进行治疗和预防的方法
TWI588153B (zh) * 2012-05-18 2017-06-21 中國醫藥大學 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6933272B1 (en) * 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
US20040097467A1 (en) * 2002-08-22 2004-05-20 Vijaya Juturu Arginine silicate inositol complex and use thereof
TWI345470B (en) 2003-03-14 2011-07-21 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
MXPA06008180A (es) * 2004-01-20 2006-08-31 Astellas Pharma Inc Metodo para tratar disfuncion erectil.
CA2654408C (en) * 2006-06-06 2018-05-08 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
GB0812019D0 (en) * 2008-07-02 2008-08-06 Asterion Ltd Insulin
CZ2013105A3 (cs) * 2010-07-15 2013-05-22 Iliich Epshtein@Oleg Zpusob zvýsení úcinku aktivované potencované formy protilátky
DE112011102349T5 (de) * 2010-07-15 2013-04-18 Oleg Iliich Epshtein Pharmazeutische Zusammensetzung und Behandlungsverfahren
EP2593474A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
BR112013001296A2 (pt) * 2010-07-21 2017-12-19 Lliich Epshtein Oleg composições farmacêuticas e respectivo uso e métodos de tratamento de vertigem de diferentes origens, cinetose e distonia vascular vegetativa
AU2011281247B2 (en) * 2010-07-21 2015-07-30 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition

Also Published As

Publication number Publication date
ES2445846R1 (es) 2015-01-02
CZ2013124A3 (cs) 2013-06-12
ITTO20110627A1 (it) 2012-01-22
GB201302924D0 (en) 2013-04-03
EP3693018A1 (en) 2020-08-12
CA2805961A1 (en) 2012-01-26
CL2013000200A1 (es) 2015-01-23
EP2595658A2 (en) 2013-05-29
DE112011102396T5 (de) 2013-05-02
NZ606964A (en) 2015-08-28
CN103118707A (zh) 2013-05-22
SG187578A1 (en) 2013-03-28
GB2552405A (en) 2018-01-24
GB201707872D0 (en) 2017-06-28
AU2011281240A1 (en) 2013-03-07
EA201300124A1 (ru) 2013-12-30
LT5980B (lt) 2013-12-27
US20130064824A1 (en) 2013-03-14
BR112013001299A2 (pt) 2017-11-21
NO20130265A1 (no) 2013-04-18
FI20135152A7 (fi) 2013-02-21
GB2496799B (en) 2017-11-22
FI20135152L (fi) 2013-02-21
SE1350212A1 (sv) 2013-04-22
DK201370089A (en) 2013-02-19
AU2011281240B2 (en) 2016-07-07
AR082312A1 (es) 2012-11-28
KR20130103486A (ko) 2013-09-23
PH12013500140A1 (en) 2013-03-11
ES2445846A2 (es) 2014-03-05
EA029847B1 (ru) 2018-05-31
EE05761B1 (et) 2016-03-15
MY160979A (en) 2017-03-31
GB2552405B (en) 2018-05-30
FR2962913A1 (fr) 2012-01-27
JP2016222684A (ja) 2016-12-28
WO2012010966A3 (en) 2012-03-29
JP2013533268A (ja) 2013-08-22
GB2496799A (en) 2013-05-22
WO2012010966A2 (en) 2012-01-26
MX2013000804A (es) 2013-10-28
EE201300007A (et) 2013-08-15
KR20180127515A (ko) 2018-11-28
US8617555B2 (en) 2013-12-31
LT2013018A (lt) 2013-10-25

Similar Documents

Publication Publication Date Title
PE20130815A1 (es) Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos
MX388904B (es) Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiento de la obesidad.
MX2013008376A (es) Composiciones y metodos para el tratamiento de cancer.
PE20151239A1 (es) Derivados de exendina-4 funcionalizada
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
EA201690494A1 (ru) Ацилированные аналоги глюкагона
EA201590294A1 (ru) Аналоги глюкагона
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
CO6620028A2 (es) Imidazoles 2-piridil sustituidos como inhibidores terapéuticos de alk5 y/o alk 4
NI201100162A (es) Derivados de indol como antagonistas del receptor crth2
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
AR080301A1 (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
CO6612271A2 (es) Anticuerpos anti-cd40
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
ECSP13012871A (es) Moduladores del receptor de glucagón
PE20140982A1 (es) Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta

Legal Events

Date Code Title Description
FC Refusal